The Industry Theaters and Mini Industry Theaters take place in the Exhibit Hall. (Photo: R.C. Photographic Productions)
With increasing popularity of Industry Theaters, ATS 2015 will deliver more offerings than ever before. Professionals will lead a total of 19 Industry Theater and Mini Industry Theater discussions in the Exhibit Hall. Have lunch while learning about new product launches and treatment options. Complimentary boxed lunch will be provided by the ATS while supplies last.
Today
11:45 a.m. to 12:30 p.m.
Industry Theater 1
Exploring Risk Reduction in Thrombosis
This lecture will discuss treatment options for patients with deep vein thrombosis and pulmonary embolism, and how they can reduce the risk of recurrent thrombotic events. This promotional educational activity is not accredited. The program content is developed by Janssen Pharmaceuticals, Inc. Speakers are present on behalf of the company and are required to present information in compliance with FDA requirements for communications about its medicines. In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company sponsored programs.
Speaker: Joseph K. Choo, MD, FACC, Interventional Cardiologist, Ohio Heart and Vascular Center, Inc., Cincinnati, OH
Company: Janssen Pharmaceuticals, Inc.
1 to 1:45 p.m.
Industry Theater 1
Personalized Medicine: Dealing with Breathlessness, Dealing with Risk
(Open to non-U.S. attendees only)
GSK is committed to the discovery and development of innovative respiratory solutions and furthering disease understanding to enable people with asthma and COPD to do more, feel better, and live longer. We believe that the opportunity for scientific discussion provided by congresses plays an important role in realizing this commitment.
Speakers: Chair: Neil Barnes, Medical Head, Global Respiratory Franchise, GSK; Dave Singh, Dealing with Breathlessness, Professor of Clinical Pharmacology and Respiratory Medicine, University of Manchester, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK; and Ian Pavord Dealing with Risk, A Role for Biomarkers? Professor of Respiratory Medicine, University of Oxford, Oxford, UK
Company: GlaxoSmithKline
11:45 a.m. to 12:30 p.m.
Industry Theater 2
Factors to Consider in the Diagnosis and Management of Allergic Asthma: A Modular Speaker Program
Allergic asthma is a heterogeneous disease. You are cordially invited to join us for an engaging and actionable discussion about the heterogeneity and complexity of allergic asthma, as well as the clinical assessment of its control.
Speaker: Kevin Murphy, MD, Boys Town National Research Hospital, Boys Town, NE
Company: Genentech, Inc.
1 to 1:45 p.m.
Industry Theater 2
Do You Have a Patient with Shortness of Breath Due to a Chronic PE? Have You Considered CTEPH
Chronic thromboembolic pulmonary hypertension (CTEPH) is the only potentially curable (via pulmonary thromboendarterectomy, PTE) form of pulmonary hypertension (PH). Because it is potentially curable, it’s vitally important that CTEPH not be mistaken for other forms of PH or for a “chronic” pulmonary embolism (PE) or “unresolved clot.” Attendees will better understand CTEPH and its relation to acute PE, and they will appreciate the importance of reasonable suspicion, accurate diagnosis, and timely referral to an experienced center.
Speakers: Gustavo Heresi-Davila, MD, Assistant Professor of Medicine, Medical Director, Pulmonary Thromboendarterectomy Program, Department of Pulmonary and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH, CTEPH.com Editorial Board Member, and Michael Madani, MD, Professor and Chief, Cardiovascular & Thoracic Surgery, Director, Sulpizio Cardiovascular Center-Surgery, Surgical Director, UCSD PTE Program, University of California San Diego Medical Center, San Diego, CA, CTEPH.com Editorial Board Member
Company: Bayer HealthCare Pharmaceuticals
11:30 a.m. to Noon
Mini Industry Theater
The Evolving Role of Parenteral Therapy in PAH
Join us for a live presentation about the evolving role of parenteral therapy in light of guideline and therapy updates, as well as discussion of a communication technique to help optimize the parenteral therapy conversation and increase patient understanding.
Company: United Therapeutics Corporation
12:30 to 1 p.m.
Mini Industry Theater
IPF Expert Perspective: Clinical Features, Progression, and Monitoring of Disease
IPF (Idiopathic Pulmonary Fibrosis) remains a challenging disease to diagnose and manage. Please join an IPF expert for an engaging dialogue about clinical manifestations, the unpredictable course, and monitoring of IPF. The program will focus on topics highly relevant to physicians and other health care professionals treating IPF patients.
Company: Genentech, Inc.
1:30 to 2 p.m.
Mini Industry Theater
A Voyage Through the Lungs: Cytokines, Effector Cells, and Clinical Biomarkers in Asthma
Join us for an interactive exploration of the pathophysiology of moderate to severe asthma. Discover the origins of hallmark signs such as airway hyperreactivity and mucus overproduction; explore the role of important Th2 cytokines such as IL-13, IL-4 and IL-5; and learn how biomarkers can reflect the activity of those cytokines.
Company: Genentech, Inc.